Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence

BACKGROUND AND PURPOSE: Current guidelines do not recommend the use of intravenous recombinant tissue plasminogen activator in patients with acute ischemic stroke who receive direct oral anticoagulants. While the humanized monoclonal antibody idarucizumab can quickly reverse the anticoagulant effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Pikija, Slaven, Sztriha, Laszlo K., Sebastian Mutzenbach, J., Golaszewski, Stefan M., Sellner, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573762/
https://www.ncbi.nlm.nih.gov/pubmed/28808918
http://dx.doi.org/10.1007/s40263-017-0460-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573762/
https://www.ncbi.nlm.nih.gov/pubmed/28808918
http://dx.doi.org/10.1007/s40263-017-0460-x

Ejemplares similares